Teladoc Health (NYSE:TDOC – Get Assessed) it was upgraded by StockNews.com research analysts to a “sell” rating in a research note released Thursday.
Several other brokers have also recently released reports on TDOC. Guggenheim upgraded Teladoc Health’s shares from a “sell” rating to a “neutral” rating in a research report on Monday, Oct. 24. DA Davidson cut its price target on Teladoc Health shares from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, October 25. Barclays reduced its price target on shares of Teladoc Health from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Thursday, October 27. Citigroup cut its price target on Teladoc Health shares from $36.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday, Dec. 13. Finally, on Thursday, Oct. 27, Oppenheimer cut its price target on Teladoc Health stock from $55.00 to $45.00. One stock research analyst rated the stock with a sell rating, twenty-two gave a hold rating, and four gave a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $48.21.
Performance of Teladoc Health shares
Teladoc Health shares opened at $23.34 on Thursday. The company has a quick ratio of 2.99, a current ratio of 3.13, and a debt-to-equity ratio of 0.25. The company has a market cap of $3.78 billion, a PE of -0.38, and a beta of 0.98. The company has a fifty-day simple moving average of $27.29 and a two hundred day simple moving average of $31.04. Teladoc Health has a twelve-month low of $22.35 and a twelve-month high of $92.06.
Teladoc Health (NYSE:TDOC – Get Rating) last released its quarterly earnings data on Wednesday, October 26. The health care provider reported ($0.45) EPS for the quarter, beating the ($0.59) consensus estimate by $0.14. The company reported revenue of $611.40 million during the quarter, compared to the consensus estimate of $609.45 million. Teladoc Health had a negative net margin of 424.40% and a negative return on equity of 2.47%. Research analysts expect Teladoc Health to post -1.4 EPS for the current year.
Insider transactions at Teladoc Health
In other Teladoc Health news, insider Arnnon Geshuri sold 2,398 shares of the company in a deal that took place on Monday, Nov. 28. The stock sold at an average price of $27.35, for a total value of $65,585.30. As a result of the transaction, the insider now directly owns 74,317 shares of the company, valued at approximately $2,032,569.95. The sale was disclosed in a filing with the SEC, accessible through the SEC’s website. In the most recent quarter, insiders sold 3,925 shares of the company for a value of $105,198. 1.55% of the shares are currently owned by company insiders.
Institutional income and expenses
Several large investors have recently bought and sold shares in TDOC. AdvisorNet Financial Inc increased its position in Teladoc Health by 456.6% in the second quarter. AdvisorNet Financial Inc now owns 3,050 shares of the health care provider worth $101,000 after purchasing an additional 2,502 shares during the most recent quarter. Vontobel Holding Ltd. increased its position in Teladoc Health shares by 66.0% during the 2nd quarter. Vontobel Holding Ltd. now owns 103,286 shares of the healthcare provider valued at $3,548,000 after purchasing an additional 41,077 shares during the period. DnB Asset Management AS increased its position in Teladoc Health by 128.2% in the second quarter. DnB Asset Management AS now owns 52,320 shares of the healthcare provider valued at $1,738,000 after purchasing an additional 29,395 shares during the most recent quarter. Waypoint Wealth Partners Inc. purchased a new position in Teladoc Health in the second quarter for $267,000. Finally, Bailard Inc. acquired a new stake in Teladoc Health stock in the second quarter valued at $207,000. Institutional investors hold 84.14% of the company’s shares.
Teladoc healthcare company profile
Teladoc Health, Inc provides virtual health services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure and mental health conditions.
This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Teladoc Health, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Teladoc Health wasn’t on the list.
While Teladoc Health currently has a “Hold” rating among analysts, senior analysts believe these five stocks are better buys.
View the five titles here